Amorcyte receives patent for chemotactic hematopoietic stem cell product

Amorcyte receives patent for chemotactic hematopoietic stem cell product
Amorcyte, Inc., a biopharmaceutical company developing cell therapy products to treat cardiovascular disease, today announced that it has been granted United States Patent number 7,794,705 titled “Compositions and Methods of Vascular Injury Repair.” The patent contains both composition of matter and method claims surrounding therapeutic chemotactic hematopoietic stem cell products used in …